We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00059449
First Posted: April 29, 2003
Last Update Posted: January 13, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  Purpose
Necrotizing enterocolitis (NEC) is a serious gastrointestinal disorder that primarily affects preterm infants. About 10% of babies less than 32 weeks gestation at birth will develop it. Overall, 30% of babies who develop NEC will die from it, with many others developing long term gastrointestinal problems. The most important factor in its development is a premature intestinal tract. Epidermal growth factor (EGF) is an important growth factor in the development and maintenance of the gastrointestinal tract. This study will look for a relationship between EGF levels in premature babies and the development of NEC.

Condition
Necrotizing Enterocolitis Premature Birth

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis

Resource links provided by NLM:


Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Estimated Enrollment: 372
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 72 Hours   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Gestational Age greater than 23 weeks at birth
  • Birth weight greater than 500 grams
  • Age less than 72 hours of life
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00059449


Locations
United States, Ohio
Good Samaritan Hospital
Cincinnati, Ohio, United States, 45220
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
University Hospital
Cincinnati, Ohio, United States, 45229
Sponsors and Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  More Information

ClinicalTrials.gov Identifier: NCT00059449     History of Changes
Other Study ID Numbers: EGFDNE (completed)
First Submitted: April 25, 2003
First Posted: April 29, 2003
Last Update Posted: January 13, 2010
Last Verified: January 2010

Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
Enterocolitis

Additional relevant MeSH terms:
Enterocolitis
Enterocolitis, Necrotizing
Premature Birth
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Mitogens
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action